If your clinical practice engages in the treatment of hemodialysis patients, Artegraft’s natural advantages should enhance your surgical experience and possibly solve several of the clinical problems encountered with ePTFE:
- Failed or immature native fistula
- Infected graft
- Recurrent clotting with synthetic graft or fistula
- Lower thigh access
- Interposition in a fistula with a ruptured aneurysm
- Hypotension
- Low protein condition where seroma formation may occur
- Renal pre-transplant
If you would like a trial, simply contact your Artegraft distributor rep (How to Buy) or click Contact Us, and request the Operating Room to issue a scrub purchase order for the Artegraft product code you wish to evaluate.
We are so confident that our Collagen Vascular Graft will exhibit superior primary patency compared to any brand of ePTFE, that Artegraft will reimburse the unit cost of the trial graft if you don’t see similar clinical results*.
*Clinical results as published in the Journal of Vascular Surgery, Volume 53, Issue 6, Pages 1640-1648, June 2011, A Prospective, randomized comparison of bovine carotid artery and expanded polytetrafluroethylene for permanent hemodialysis vascular access.